International Game Technology (IGT) on Thursday saw its shares slide over 7% after reporting fourth-quarter earnings of 24 cents per share, 7 cents shy of the Wall Street expectation. On a GAAP basis, the company swung to a loss of 50 cents per share from a profit of 39 cents per share in the year-over period.
Revenue fell 6% year-over-year to $1.27 billion, driven by Sports Betting dynamics in the prior year. However, the top line was in line with the street expectation.

Revenue from the North America Gaming and Interactive segment was $275 million, down 1% in a constant currency basis. The North American Lottery segment, meanwhile, grew 2% to $309 million. While revenue fell 18% in the International segment, in Italy, it was more or less flat compared to the same quarter last year.
For 2019, the UK-based firm expects adjusted EBITDA of $1.70 million to $1.76 billion. Capital expenditures for the same period are anticipated between $450 million and $550 million.
READ: Gaming stocks: A look at the three major players
CEO Marco Sala said, “We’ve established solid foundations to build on – securing large, long-term Lottery contracts in key markets and executing a full refresh of our gaming machine cabinet and content portfolio. These efforts will translate into improved free cash flow beginning in 2019.”
IGT shares have declined 38% in the trailing 52 weeks. Since the beginning of this year, the stock has gained over 3%.
Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs